Researchers at Signature Characterize Previously Unrecognized Genetic Disorder
Posted on: Wednesday, 8 October 2008, 12:00 CDT
Researchers at Signature Genomic Laboratories recently reported two individuals with microscopic losses of DNA from the long arm of chromosome 16 and suggested this deletion represents a previously unappreciated syndrome.
In the study, published in the journal Clinical Genetics, the two individuals with deletions of the long arm of chromosome 16 were identified among more than 22,000 patients with unexplained mental retardation and birth defects referred to Signature for testing. Both patients' deletions encompassed the gene SALL1, mutations of which are hypothesized to cause Townes-Brocks syndrome, a rare autosomal-dominant condition characterized by anal, renal, limb, and ear malformations. However, neither individual had clinical features suggestive of Townes-Brocks syndrome, and their common clinical features, as well as those of individuals in another report, suggested deletions of this segment of chromosome 16 represented a distinct, emerging syndrome.
"Although further studies are required to determine what role these deletions play in the patients' clinical features, microarray analysis was essential for identifying this novel chromosome abnormality. Their highly variable clinical features--and the rarity of similar patients reported in the literature--would have prevented their identification without this technology," said Dr. Blake C. Ballif, Ph.D., Director of Product Development and Research at Signature and lead author of the study. "These cases are an excellent example of how microarray technology can provide answers that traditional methods cannot."
About Signature Genomic Laboratories
Signature Genomic Laboratories, founded in 2003, was the first laboratory to provide microarray-based cytogenetic diagnostics with its proprietary SignatureChip(R) and is the leader in providing microarray-based chromosome analysis. Signature's worldwide client base includes clinical geneticists, neurologists, pediatricians, neonatologists, obstetricians, and the research community. Signature is CAP accredited, CLIA certified, and has clinical licenses from California, Rhode Island and Florida. Additional information about Signature Genomic Laboratories is available at www.signaturegenomics.com.
Source: Business Wire
Related Articles
- TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia
- Twenty-One Hospitals Across the Rocky Mountain States Come Together to Focus on Improving Clinical Quality and Patient Safety
- Twenty-One Hospitals in the Midwest Coming Together to Focus on Improving Clinical Quality and Patient Safety
- Eisai Provides Preliminary Efficacy Update On EORTC Phase III Trial of Dacogen(R) Versus Supportive Care in Patients With Myelodysplastic Syndromes
- 21 Hospitals in Louisiana, Mississippi and Tennessee Come Together to Focus on Improving Clinical Quality and Patient Safety
- B.C. Wins Showdown With Private Clinic; Clinic Won't Bill Patients
- Covalent Group, Inc. Signs $2.2 Million Contract With New Sponsor to Conduct Clinical Trial in Patients With Cardiovascular Disease
- Effects of Lipo-Prostaglandin E^Sub 1^ on Pulmonary Hemodynamics and Clinical Outcomes in Patients With Pulmonary Arterial Hypertension*
- Periacetabular Osteotomy in Patients With Down's Syndrome
- Cardiovascular Care of Patients With Marfan Syndrome
 |
 |
User Comments (0)
RSS Feeds